Champions Oncology (CSBR) Operating Margin (2010 - 2026)
Champions Oncology (CSBR) posted quarterly Operating Margin of 3.77% for Q2 2026, up 1247.0% year-over-year from 0.28% in Q2 2025, and down 126.37% quarter-over-quarter from 1.67% in Q1 2026.
Champions Oncology (CSBR) Operating Margin (2010 - 2026) Analysis & Trends
Champions Oncology's Operating Margin history runs 17 years deep, the most recent figure standing at 3.77% for Q2 2026.
- In Q2 2026, Operating Margin rose 1247.0% year-over-year to 3.77%; the TTM figure through Apr 2026 stood at 1.92% (down 991.0% YoY), while the FY2026 annual figure was 1.92%, down 991.0% from the prior year.
- Operating Margin for Q2 2026 stood at 3.77%, down from 1.67% in the prior quarter.
- The five-year high for Operating Margin was 26.4% in Q1 2025, with the low at 21.44% in Q1 2024.
- The 5-year median for Operating Margin is 2.24% (2022), against an average of 4.46%.
- The sharpest annual moves came in 2025 and 2026: Operating Margin jumped 4785 bps in 2025, then plunged 2807 bps in 2026.
- Champions Oncology's Operating Margin stood at 0.05% in 2022, then slumped by 34564 bps to 16.89% in 2023, then jumped by 132 bps to 5.43% in 2024, then tumbled by 77 bps to 1.23% in 2025, then sank by 407 bps to 3.77% in 2026.
- Business Quant data shows CSBR's Operating Margin at 3.77% in Q2 2026, 1.67% in Q1 2026, and 1.23% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | -3.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -3.77% |
| Jan 31, 2026 | -1.67% |
| Oct 31, 2025 | 1.23% |
| Jul 31, 2025 | -3.77% |
| Apr 30, 2025 | -16.24% |
| Jan 31, 2025 | 26.40% |
| Oct 31, 2024 | 5.43% |
| Jul 31, 2024 | 9.45% |
| Apr 30, 2024 | -1.94% |
| Jan 31, 2024 | -21.44% |
| Oct 31, 2023 | -16.89% |
| Jul 31, 2023 | -20.32% |
| Apr 30, 2023 | -19.29% |
| Jan 31, 2023 | -19.24% |
| Oct 31, 2022 | 0.05% |
| Jul 31, 2022 | -2.07% |
| Apr 30, 2022 | -2.42% |
| Jan 31, 2022 | 6.29% |
| Oct 31, 2021 | 2.23% |
| Jul 31, 2021 | -1.56% |